Sera Prognostics, Inc. (SERA)
| Market Cap | 70.49M |
| Revenue (ttm) | 57,000 |
| Net Income (ttm) | -32.14M |
| Shares Out | 39.16M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,311 |
| Open | 1.780 |
| Previous Close | 1.800 |
| Day's Range | 1.740 - 1.810 |
| 52-Week Range | 1.560 - 4.090 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 5.50 (+208.12%) |
| Earnings Date | Aug 5, 2026 |
About SERA
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive an... [Read more]
Financial Performance
In 2025, Sera Prognostics's revenue was $81,000, an increase of 5.19% compared to the previous year's $77,000. Losses were -$31.93 million, -2.95% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for SERA stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 208.12% from the latest price.
News
Sera Prognostics part of ARPA-H award for birth safety test development
Sera Prognostics (SERA) announced its participation in a multi-institutional research program that was awarded up to $10.4M by the Advanced Research Projects Agency for Health, or ARPA-H, to develop a...
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk-- SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), f...
Sera Prognostics Transcript: AGM 2026
The meeting saw the election of two directors for terms expiring in 2029 and the ratification of Ernst & Young as auditors. Shareholders were given opportunities for questions, and management highlighted risks associated with forward-looking statements.
Craig-Hallum bullish on Sera Prognostics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Sera Prognostics (SERA) with a Buy rating and $6 price target The firm notes Sera has a proprietary test to identify asymptomatic women…
Sera Prognostics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Sera Prognostics (SERA) with a Buy rating and $6 price target
Sera Prognostics Transcript: Jefferies Global Healthcare Conference 2026
Following strong PRIME study results, investments shifted from clinical to commercial focus, extending cash runway through 2029. Key milestones include reimbursement wins, staged provider rollout, and legislative successes like Illinois Medicaid coverage, with broad awareness seen as the main adoption hurdle.
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
Sera Prognostics Proxy statement: Proxy filing
Sera Prognostics filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Sera Prognostics reports Q1 EPS (17c), consensus (17c)
Reports Q1 revenue $14K, consensus $66.67K. “In Q1, our primary focus was building awareness with clinicians and the broader stakeholder community as we continue the evolution from clinical stage to…
Sera Prognostics Earnings Call Transcript: Q1 2026
Q1 2026 saw continued investment in commercialization and advocacy, with revenue declining to $14,000 and operating expenses stable. Resource realignment is expected to reduce costs by $10 million annually, extending cash runway through 2029.
Sera Prognostics Earnings release: Q1 2026
Sera Prognostics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Sera Prognostics Quarterly report: Q1 2026
Sera Prognostics has published its Q1 2026 quarterly earnings report on May 6, 2026.
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...
Sera Prognostics Slides: Corporate presentation
Sera Prognostics has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Sera Prognostics Proxy statement: Proxy filing
Sera Prognostics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Sera Prognostics Proxy statement: Proxy filing
Sera Prognostics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
Sera Prognostics Slides: Corporate presentation
Sera Prognostics has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Sera Prognostics Earnings Call Transcript: Q4 2025
2025 saw pivotal progress with PRIME study publication, expanded payer and provider engagement, and disciplined financial management. Revenue remains modest, but strong cash reserves and a focused commercial strategy position the company for gradual adoption and growth.
Sera Prognostics Annual report: Q4 2025
Sera Prognostics has published its Q4 2025 annual report on March 18, 2026.
Sera Prognostics Earnings release: Q4 2025
Sera Prognostics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Sera Prognostics reports Q4 EPS (16c), consensus (19c)
Reports Q4 revenue $10K vs. $24K last year. In February 2025, Sera completed an underwritten public offering of common stock and pre-funded warrants extending cash runway through 2028. “2025 marked…
SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
Sera Prognostics Slides: Corporate presentation
Sera Prognostics has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.